A New Perspective on Alzheimer's Disease Biomarkers in the IVD Field
DOI:
https://doi.org/10.62051/ijphmr.v1n3.05Keywords:
Alzheimer's Disease, Hybridoma technology, Monoclonal antibody, Proximity extension assay, In vitro diagnosis, Olink, ChemiluminescenceAbstract
As a neurodegenerative disease, early diagnosis of Alzheimer's disease (AD) is essential for delaying the progress of the disease. Due to the limitations of diagnostic methods, new biomarkers and detection technologies are urgently needed. Therefore, this paper mainly discusses the research and development of specific antibodies by lymphocyte hybridoma technology and the application of proximity extension assay (PEA) methodology in the field of in vitro diagnosis (IVD) for early screening detection of AD [1]. By applying Olink proteomic analysis technology with PEA methodology, the potential value of Olink proteomic analysis technology in improving the diagnostic accuracy and early identification of AD is clearly explained, which provided new ideas for future research direction and clinical application.
References
Zeng Wei, Huang Wenchang, Zeng Rui, et al. Study on the diagnosis method of Alzheimer's disease based on near infrared water spectroscopy [J/OL]. Optoelectronic Laser, 1-10 [2024-06-12].
Yin Hongyan, You Sihan, Guo Chunyan. Research progress of core biomarkers and other biomarkers of Alzheimer's disease [J]. Acta Neuropharmacology, 2023, 13(06):45-49.
Gao Xiaojuan. Alzheimer's disease: understanding Alzheimer's disease [N]. Shanxi Science and Technology News, 2024-05-30(A03).
It is feasible or feasible to treat human Alzheimer's disease with ultrasound therapy [J]. biomedical engineering and clinical medicine, 2024, 28(03):353.
Liu Hanjie, You Maochun, Zhang Lingyu, et al. Discussion on the treatment of Alzheimer's disease based on the theory of "five internal organs are in harmony" [J]. Journal of Chengdu University of Traditional Chinese Medicine, 2024, 47(03):50-53+73.
Luo S, Wang Y, Hisatsune T. P2Y1 receptor in Alzheimer's disease [J]. Neural regeneration research, 2025, 20 (2): 440-453.
Sirkis W D, Solsberg W C, Johnson P T, et al. Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease [J]. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024.
Venkatesan D, Muthukumar S, Iyer M , et al. Heavy metals toxicity on epigenetic modifications in the pathogenesis of Alzheimer's disease (AD) [J]. Journal of biochemical and molecular toxicology, 2024, 38 (6): e23741-e23741.
Wang J H, Meyyappan CA, Feldman JO, et al. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease [J]. Expert opinion on emerging drugs, 2024.
Chen J, Rao J, Lu H, et al. Network pharmacology and experimental verification to explore the effect of Hedyotis diffusa on Alzheimer's disease [J]. Chemical biology & drug design, 2024, 103 (6): e14558-e14558.
O. S S, Abdulwasiu I, C. U. O, et al. Computational identification of potential acetylcholinesterase (AChE) and monoamine oxidase-B inhibitors from Vitis vinifera: a case study of Alzheimer’s disease (AD) [J]. In Silico Pharmacology, 2024, 12 (1): 49-49.
Sinha S, Wal P, Goudanavar P, et al. Research on Alzheimer's Disease (AD) Involving the Use of In vivo and In vitro Models and Mechanisms [J]. Central nervous system agents in medicinal chemistry, 2024.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
